FDA advisors recommend GSK's RSV vaccine for older adults, but flag potential safety risks
Publishing timestamp: 2023-03-01 15:16:49
Summary
FDA advisors recommended GlaxoSmithKline's RSV vaccine for adults ages 60 and older, but flagged potential safety issues over nervous system disorders that may be tied to the shot. They unanimously said the vaccine's efficacy data was sufficient, but raised concern over a possible link to Guillain-Barre syndrome. There were two cases of Guillain-Barre syndrome and two cases of another rare nervous system disorder during GSK's trial, including one death. FDA is expected to make its decision on GSK's vaccine by May 3.
Sentiment: MIXED
Tickers: GLAXO-IN,
Keywords: business news, biotech and pharmaceuticals, politics, coronavirus, epidemics, business, glaxosmithkline pharmaceuticals ltd, breaking news: business, biotechnology, pandemics, health care industry, u.s. economy, disease outbreaks,